logo BDSP

Base documentaire

  1. Estrogen-progestin replacement therapy and endometrial cancer.

    Article - En anglais


    It has been known for more than 20 years that estrogen replacement therapy substantially increases a woman's risk of developing endometrial cancer.

    To reduce this increased risk, progestins have been added to estrogen replacement therapy for between 5 and 15 days (usually 7 or 10 days) per « month » in a sequential fashion (sequential estrogen-progestin replacement therapy) or with each dose of estrogen replacement therapy (continuous combined replacement therapy).

    At the present time, however, little is known about the effects of varying the number of days that progestin is used in sequential estrogen-progestin replacement therapy.


    We sought to determine the effects of sequential estrogen-progestin replacement therapy and continuous combined replacement therapy on a woman's risk of developing endometrial cancer.


    A population-based, case-control study of 833 case subjects and 791 control subjects was conducted.

    Women were postmenopausal, white, and aged 50-74 years when first diagnosed with invasive endometrial cancer or were aged 50-74 years at the matching date for control subjects.

    All subjects were interviewed in person with the aid of a month-by-month calendar.

    Relative risks were estimated by odds ratios (ORs) ; ORs were adjusted simultaneously for the different forms of hormone replacement therapy and for the known endometrial cancer risk factors.


    The adjusted OR was 2.17 (95% confidence interval [CI]=1.91-2. (...)

    Mots-clés Pascal : Tumeur maligne, Endomètre, Facteur risque, Oestrogène, Progestérone, Hormone stéroïde, Traitement substitutif, Postménopause, Epidémiologie, Rythme administration, Toxicité, Etats Unis, Amérique du Nord, Amérique, Etude cas témoin, Adulte, Homme, Vieillard, Appareil génital femelle pathologie, Utérus pathologie

    Mots-clés Pascal anglais : Malignant tumor, Endometrium, Risk factor, Estrogen, Progesterone, Steroid hormone, Replacement therapy, Postmenopause, Epidemiology, Administration schedule, Toxicity, United States, North America, America, Case control study, Adult, Human, Elderly, Female genital diseases, Uterine diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0512576

    Code Inist : 002B02U10. Création : 13/02/1998.